retatrutide parkinson's disease trial nct New GLP-3 drug significantly slashes both weight and blood sugar levels in Phase III Liraglutide once daily versus placebo

Lancet (1999) 353(9167):18659

August 19, 2021

Patients with circulation disorders or bleeding conditions should consult their physician before self-injecting, as semaglutide increases bleeding risk in susceptible individuals

See more serious warnings & safety info here

Notable reductions from baseline were observed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and increases in adiponectin

Symptoms such as persistent or severe abdominal pain, significant changes in urination, or a rash combined with difficulty breathing should be treated as a medical emergency